Grant: Project Grant
Centre hospitalier de l'Université de Montréal (CHUM)
$841,500.00
Therapeutic potential of the LXA4-ALX/FPR2 axis in osteoarthritis
EF 2021-22
Résumé
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability in Canada and worldwide. It has a large impact on the patient's quality of life, and constitutes a significant socioeconomic burden. There is currently no effective treatment for OA. Therefore, the need to develop an effective therapeutic strategy is an urgent necessity.
The overarching goal of our studies is to improve our understanding of the molecular mechanisms underlying the pathogenesis of osteoarthritis with the ultimate goal of developing more effective treatments.
Our recent studies strongly suggest that the enzyme, Lipoxin A4 and its receptor ALX/FPR2 have protective properties in OA. In this project, we will use animal models of OA and human sera and synovial fluids to define the role and the therapeutic potential of this pathway in OA.
These studies will improve our understanding of the pathogenesis of OA and may be helpful in developing novel efficacious anti-OA therapeutic strategies.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
450992
Name
Fahmi Hassan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage
Projecttitle
Therapeutic potential of the LXA4-ALX/FPR2 axis in osteoarthritis
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$841,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
15-Lipoxygenase; Alx/Fpr2; Cartilage; Gene Expression; Lipoxin A4 (Lxa4); Osteoarthritis
Abstract
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability in Canada and worldwide. It has a large impact on the patient's quality of life, and constitutes a significant socioeconomic burden. There is currently no effective treatment for OA. Therefore, the need to develop an effective therapeutic strategy is an urgent necessity.
The overarching goal of our studies is to improve our understanding of the molecular mechanisms underlying the pathogenesis of osteoarthritis with the ultimate goal of developing more effective treatments.
Our recent studies strongly suggest that the enzyme, Lipoxin A4 and its receptor ALX/FPR2 have protective properties in OA. In this project, we will use animal models of OA and human sera and synovial fluids to define the role and the therapeutic potential of this pathway in OA.
These studies will improve our understanding of the pathogenesis of OA and may be helpful in developing novel efficacious anti-OA therapeutic strategies.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Fahmi, Hassan
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $841,500~ $0~
